# Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)

> **NCT02478229** · PHASE3 · TERMINATED · sponsor: **University Health Network, Toronto** · enrollment: 1 (actual)

## Conditions studied

- Hepatitis C Viral Infection

## Interventions

- **DRUG:** Sofosbuvir (SOF) and Ledipasvir (LDV)

## Key facts

- **NCT ID:** NCT02478229
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06
- **Primary completion:** 2016-04
- **Final completion:** 2016-08
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** difficulty recruiting patients
- **Last updated:** 2016-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02478229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02478229, "Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02478229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*